<DOC>
	<DOCNO>NCT01203254</DOCNO>
	<brief_summary>The purpose study assess efficacy cholestagel reduce frequency soft liquid stool per day patient CD clinical remission symptom BAM ass improvement stool consistency quality life patient assess safety cholestagel .</brief_summary>
	<brief_title>Colesevelam Treatment Bile Acid Malabsorption Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Malabsorption Syndromes</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent adequate explanation patient information . Male female patient CD 18 65 year age clinical remission Crohns Disease Activity Index ( CDAI ) score 150 less , symptom functional BAM symptom BAM small bowel resection frequency least 3 maximal 15 liquid soft stool per day . Stable medical treatment CD minimal period 3 month precede screen visit , consist either continuous oral treatment aminosalicylate , prednisolone ( maximum 10 mg/day ) , azathioprine , 6mercaptopurine , methotrexate support periodic treatment* TNFalpha AK ( Infliximab , Adalimumab , Certolizumab ) ( patient TNFalpha , dose TNFalpha coincide baseline visit ) Blood serum CRP value less equal 1 mg/dl ( 10 mg/l ) . BAM assess blood test 7Î±hydroxy4cholesten3on excretion equal 50 ng/ml Exclusion criterion : Allergy hypersensitivity component cholestagel placebo identify medical history Participation another clinical trial within period 4 week screen visit Presence addiction , alcohol abuse specific disease would allow patient understand essence requirement potential consequence participation clinical trial Signs suggestive patient unable follow visit schedule require ( example professional obligation ) Treatment cyclosporine , tacrolimus , 3 month less screening Oral Treatment antibiotic 3 week less screening Topical treatment steroid mesalazinecontaining application 3 week less screen Treatment bile acid bile acid binding agent ( e.g . Cholestayramine ) 6 week less screen Infectious disease ( HIV , hep B , hep C , tuberculosis , listeriosis , positive clostridiumdifficiletoxin proof faeces ) Current presence intraabdominal abscess Fistula Cholestatic liver disease , bowel biliary obstruction Dysphagia swallowing disorder Known malignancy history malignancy Having undergone intestinal surgery within 6 month screen Status intestinal surgery 100cm resect bowel . Short bowel syndrome Planned gastrostomy , ileostomy colostomy . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Colesevelam</keyword>
	<keyword>IBD</keyword>
	<keyword>Bile Acid Malabsorption</keyword>
	<keyword>Crohns disease</keyword>
</DOC>